Clinical aspects of brain tumor

Current Opinion in Neurology

Volumn 10, Issue 6, 1997, Pages 452-458

  Damek, Denise M ^a   Hochberg, Fred H ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LOMUSTINE; METHOTREXATE; PACLITAXEL; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

BRAIN LYMPHOMA; BRAIN TUMOR; CANCER SURVIVAL; CLINICAL PROTOCOL; GLIOBLASTOMA; GLIOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROECTODERM TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; RADIOSURGERY; REOPERATION; REVIEW;

EID: 0030728140     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199712000-00003     Document Type: Review

References (49)

1. Ammirati M, Galicich JH, Arbit E: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 1987, 21:607-614.
2. Harsh GR. Levin VA, Gutin PH: Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 1987, 21:615-621.
3. Prados MD: Treatment strategies for patients with recurrent brain tumors. Semin Radiat Oncol 1991, 1:62-68.
4. Scharfen DO, Sneed PS, Wara WM: High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 1992, 24:593-597.
5. McDermott MW, Sneed PK, Prados MD et al.: Results of Radiosurgery for Recurrent Malignant Gliomas Boston: International Radiosurgery Society. 1995:69.
6. Shrieve DC, Alexander E, Wen PY, Fine HA, Kooy HM, Black PMcL, Loeffler JS: Comparison of stereotactic radiosurgery and brachy-therapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995, 36:275-282.
7. Shepherd SFLR, Warrington AP, Graham J, Mines F, Brada M: Hypofractionated Stereotactic Radiotherapy in the Management of Recurrent Glioma. Boston: International Radiosurgery Society, 1995:66.
8. Masciopinto JE, Levin AB, Mehta MP, Rhode BS: Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg 1995, 82:530-535.
9. Shaw E, Scott C, Souhami L, Dinapoli R, Bahary J-P, Kline R, Wharam M, Schultz C, Davey P, Loeffler J et al.: Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of Radiation Therapy Group Protocol 90-05. Int J Radiat Oncol Biol Phys 1996, 34:647-654. This prospective multicenter dose escalation study evaluated single fraction radiosurgery in 102 previously irradiated glioma and brain metastases patients. The incidence of acute toxicity was < 10% in patients with lesions ≤ 40 mm in maximum diameter. Operation for symptomatic radionecrosis was required in 6% of patients.
10. Deshmukh A, Scott JA, Palmer EL, Hochberg FH, Gruber M, Fischman AJ: Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma. Clin Nucl Med 1996, 21:720-725.
11. O'Reilly SM, Harte RJA, Newlands ES, Jones T, Price PM: Early changes in tumor glucose metabolism may predict and quantify response of gliomas to chemotherapy: a phase II study using temozolomide [Abstract]. Proc Am Soc Clin Oncol 1995, 14:1635.
12. Taylor JS, Langston JW, Reddick WE, Kingsley PB, Ogg RJ: Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int J Radiat Oncol Biol Phys 1996, 36:1251-1261. MRS was shown to differentiate recurrent tumor from delayed cerebral necrosis and normal brain with reasonable accuracy. The authors proposed a novel diagnostic index based on peak areas for choline and creatine compounds as a quantitative measure to facilitate rapid objective interpretation of data.
13. Shimizu H, Kumabe T, Taylor JS, Langston JW, Reddick WE, Kingsley PB, Ogg RJ, Tominaga T, Kayama T, Hara K et al.: Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. Am J Neuroradiol 1996, 17:737-747. A semiquantitative approach was introduced for magnetic resonance spectral analysis by use of an external reference. Statistically significant differences between low-grade and high-grade gliomas were shown in the semiquantitative values of choline-containing compounds and N-acetyl aspartate.
14. Bruening R, Kwong KK, Vevea MJ, Hochberg FH, Cher L et al.: Echoplanar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. Am J Neuroradiol 1996, 17:831-840.
15. Tsuchiya K, Mizutani Y, Hachiya J: Preliminary evaluation of fluid-attenuated inversion-recovery MR in the diagnosis of intracranial tumors. Am J Neuroradiol 1996, 17:1081-1986.
16. Lippitz BE, Scheitinger C, Scholz M, Weis J, Gilsbach JM, Fuzesi LL: Cytogenetic analysis of gliomas by in situ hybridization of stereotactic biopsy material. Acta Neurochir (Wien) 1997, 139:22-25. This study demonstrated the feasibility and quantitative evaluability of chromosomal in-situ hybridization for Stereotactic brain biopsy specimens.
17. Arnoldus EPJ, Wolters LBT, Voormolen JHC, VanDuinen SG, Raap AK, VanDerPloeg M, Peters ACB: Interphase cytogenetics: a new tool for the study of genetic changes in brain tumors. J Neurosurg 1992, 76:997-1003.
18. James CD, Carlbom E, Dumanski JP, Hansen M, Nordenskjold M, Collins P, Cavenee WK: Clonal genomic alterations in glioma malignancy stages. Cancer Res 1988, 48:5546-5551.
19. Hopman AHN, Podenghe P, Moesker O, Ramaekers FCS: Interphase cytogenetics: an approach to the detection of genetic aberrations in tumors. In Diagnostic Molecular Pathology: a Practical Approach, Vols 1 and 2. Edited by Herrington C, McGee JO'D, Oxford: IRL at Oxford University Press, 1441-1467.
20. Venter DJ, Thomas DGT: Multiple sequential molecular abnormalities in the evolution of human gliomas. Br J Cancer 1991, 63:753-757.
21. Hsu SC, Volpert OV, Steck PA, Mikelsen T, Polverini PJ, Rao S, Chou P, Bouck NP: Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 1996, 56:5684-5691. This paper presents data demonstrating the role of a gene on chromosome 10q in preventing astrocytomas from developing into glioblastomas by virtue of inducing the secretion of thrombospondin-1 and thereby limiting angiogenesis. The therapeutic implications are discussed.
22. Glantz MJ, Choy H, Akerley W, Kearns CM, Egorin MJ, Rhodes CH, Cole BF: Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. Semin Oncol 1996, 23(suppl 16):128-135. This report describes a single institution experience with weekly outpatient paclitaxel administration, with and without concurrent external beam radiation, in patients with astrocytic brain tumors and non-small cell lung cancer. Drug activity, pharmacokinetics, and range of toxicities are systematically evaluated.
23. Hawkins DS, Demers GW, Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996, 56:892- 898.
24. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996, 2:72-79.
25. Zhang W, Hinton DR, Surnock AA, Couldwell WT: Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report. Neurosurgery 1996, 38:587-590.
26. Piepmeier J, Christopher S, Spencer D, Byrne T, Kim J, Knisel JP, Lacy J, Tsukerman L, Makuch R.: Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 1996, 38:872-879. A retrospective analysis of 55 patients with low-grade astrocytomas evaluating specific outcome factors is presented.
27. Recht LD, Lew R, Smith TW: Suspected low-grade glioma: is deferring treatment safe? Ann Neurology 1992, 31:431-436.
28. van Kampen M, Engenhart-Cabillic R, Debus J, Hess T, Schad LR, Wannenmacher MF: Low-grade astrocytoma: treatment with conventionally fractionated stereotactic radiation therapy. Radiology 1996, 201:275-278. This paper reports the use of stereotactic RT as the primary treatment modality in 24 symptomatic patients with inoperable low-grade gliomas. Clinical symptoms improved or stabilized in > 90% of the patients 5 months after treatment. Median time to disease progression after RT was 48 months. All treatment failures occurred within the planning target volume.
29. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996, 46:203-207. This paper reports the use of PCV chemotherapy in nine symptomatic patients with low-grade oligodendroglioma tumors.
30. Brandes AA, Rigon A, Zampieri P, Scelzi E, Amista P, Berti F, Rotilio A, Gardiman M, Florentine MV: Early chemotherapy and concurrent radiochemotherapy in high grade glioma. J Neuro-Oncol 1996, 30:247-255. Twenty-four patients with newly diagnosed high-grade gliomas received early postoperative chemotherapy with BCNU, concurrent radiochemotherapy with carboplatin and teniposide, and then postradiotherapy BCNU. Objective response and disease stabilization rates were similar to those seen with standard treatments.
31. Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P, Rice Edwards JM, Illingworth RD, Richards PG: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996, 32:2236-2241. A single institution experience of 75 patients with malignant gliomas administered temozolomide either as adjuvant therapy at initial diagnosis or salvage therapy at disease recurrence is presented. Temozolomide did demonstrate activity against high-grade glioma but, overall, the responses were short-lived and had relatively little impact on survival.
32. Kim L, Hochberg FH, Thornton AF, Harsh GR, Patel H, Finkelstein D, Louis DN: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 1996, 85:602-607. Twenty-five patients with malignant oligoastrocytomas and seven patients with anaplastic oligodendroglial tumors were administered PCV chemotherapy as either neoadjuvant or adjuvant therapy. Durable responses to chemotherapy were achieved. As little as a 5% oligodendroglial component in a mixed glioma can confer chemosensitivity.
33. Lunardi P, Osman Farah J, Mastronardi L, Puzzilli F, Lo Bianco FM: Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study. Acta Neurochir (Wien) 1996, 138:215-220. This is a phase II clinical study comparing intravenous high-dose carboplatin provided to patients with newly diagnosed malignant gliomas in the immediate post-operative period as well as during and after radiation with adjuvant BCNU chemotherapy.
34. Chamberlain MC: Salvage chemotherapy with Taxol for recurrent oligodendrogliomas [Abstract]. Neurology 1997, 48:A26.
35. Cascino TL, Veeder MH, Buckner JC, O'Fallon JR, Wiesenfeld M, Levitt R, Goldberg RM, Kuross SA, Morten RF, Schaithaver BW: Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. J Neurooncol 1996, 30:243-246. A multi-institutional prospective trial of 30 patients with recurrent primary brain tumors treated with a combination of 5-fluorouracil and leucovorin is presented. The regimen demonstrated minimal efficacy.
36. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo MLJ, Masri L, Law RE, Weiss MH: Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996, 2:619-622. This paper presents data from 32 patients with recurrent malignant gliomas treated with high-dose daily tamoxifen. Clinical and radiographic responses were seen in eight patients (25%) and stable disease was noted in six additional patients. The median survival from the initiation of tamoxifen was 16 months for the anaplastic astrocytoma group, 7.2 months for the glioblastoma group, and 10.1 for the entire cohort.
37. Bouffet E, Mottolese C, Jouvet A, Philip I, Frappaz D, Carrie C, Brunot- Mentigny M: Etoposide and thiotepa followed by ABUT (autologous bone marrow transplantation) in children and young adults with high-grade gliomas. Eur J Cancer 1997, 33:91-95. This is a report of a single institution experience of high-dose etoposide and thiotepa followed by autologous bone marrow transplantation in 22 children and young adults. Survival was no better than that reported with conventional treatments.
38. Cairncross G, Swinnen L, Stiff P, Rosenfeld S, Vaughan W, Paleologos N, Kaminer L, DeAngelis L, Nimer S, Dropcho E: High-dose thiotepa with hematopoietic reconstitution (deferring radiation) for newly diagnosed aggressive oligodendroglioma [Abstract]. Proc Am Soc Clin Oncol 1997, 16:388.
39. Smith A, Rosenfeld S, Dropcho E, Vaughan W, Swinnen L, Stiff P, Paleologos N, Kaminer L, Peterson K, DeAngelis L et al.: High-dose thiotepa with hematopoietic reconstitution for recurrent aggressive oligodendroglioma [Abstract]. Proc Am Soc Clin Ocol 1997, 16:409.
40. Balmaceda C, Hesdorffer C, Pappadoupolous K, Simmons T, Vahdat L, Garret T, Antman K, Fetell MR: Feasibility of high-dose chemotherapy (HDC) followed by autologous or stem cell support for recurrent/progressive oligodendroglioma [Abstract]. Neurology 1997, 48:A18.
41. Brem H, Piantadosi S, Burger PCS, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G et al.: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995, 345:1008-1012.
42. Olivi A, Gilbert M, Duncan KL, Corden B, Lenartz D, Brem H: Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study. Cancer Chemother Pharmacol 1993, 31:449-454.
43. Weingart J, Tyler B, Colvin OM, Brem H: Local delivery of camptothecin as a new treatment for malignant brain tumors. Third NIH Drug Discovery and Development Symposium, San Diego, California; 1993.
44. Walter KA, Cahan MA, Gur A, Domb A, Brem H: Interstitial Taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 1994, 54:2207-2212.
45. Judy KD, Olivi A, Buahin KG, Domb A, Epstein JI, Calvin OM, Bam H: Controlled release of a cyclophosphamide derivative with polymers is effective against rat gliomas. J Neurosurg 1995, 82:103-108.
46. Bauman GS, Sneed PK, Wara WM, Stalpers LJA, Chang SM, McDermott MS, Gutin PH, Larson DA: Reirradiation of primary CNS tumors. Int J Radiat Oncology Biol Phys 1996, 36:433-441. This is a retrospective review of 34 patients with recurrent primary brain tumors retreated with fractionated external beam irradiation. Concomitant chemotherapy or surgery was provided in most patients. Reirradiation was associated with only modest palliative and survival benefits.
47. Abrey LE, Yahalom J, DeAngelis LM: Relapse and late neurotoxicity in primary central nervous system lymphoma (PCNSL) [Abstract]. Neurology 1997, 48:A18.
48. Sherman W, Balmaceda C, Nichols G, Mears G, Antman K: Feasibility of 3g/m2 of intravenous methotrexate (IVMTX) for primary central nervous system lymphoma (PCNSL) [Abstract]. Neurology 1997, 48:A17.
49. Cher L, Glass J, Harsh GR, Hochberg FH: Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 1996, 46:1757-1759. This paper presents results from a retrospective review of patients with primary brain lymphoma treated with methotrexate-based chemotherapy and deferred RT. Deferring brain irradiation is feasible and practical, and appears to provide durable complete responses without significant or irreversible acute or long-term toxicity.